Module

Hepatitis B Virus Resistance for Clinicians

Source: Hepatitis Annual Update 2006

Hepatitis B Virus Resistance for Clinicians


Program Director: Emmet B. Keeffe, MD, MACP

Faculty:

  • Anna S. F. Lok, MD

CME CREDIT INFORMATION

Release Date: 08/04/06

Expiration Date: 08/03/07


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status



Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the methods used to detect antiviral-resistant forms of HBV
  • Review ways to prevent the development of antiviral-resistant HBV
  • Discuss the management of antiviral-resistant HBV

Topics covered include:

  • Introduction
  • Why Do Antiviral-Resistant HBV Mutants Arise?
  • Identifying Resistance Mutations
  • Rates of Genotypic Resistance to HBV Nucleos(t)ide Analogue Therapies
  • Detection, Prevention, and Consequences of Antiviral-Resistant HBV
  • Containment of Antiviral-Resistant HBV
  • Conclusions and Summary


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.